Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.2.67
K. Tolba
{"title":"Competing Immune Biomarkers in the Selection of First-line Therapy in Non-small Cell Lung Cancer","authors":"K. Tolba","doi":"10.17925/OHR.2018.14.2.67","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.2.67","url":null,"abstract":"","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.2.70
S. Chun
{"title":"Treatment Disparities in Small Cell Lung Cancer","authors":"S. Chun","doi":"10.17925/OHR.2018.14.2.70","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.2.70","url":null,"abstract":"","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597544","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.2.72
W. Bahou
{"title":"Platelet Biomarkers for Precision Medicine in Hematology and Oncology","authors":"W. Bahou","doi":"10.17925/OHR.2018.14.2.72","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.2.72","url":null,"abstract":"","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.2.65
M. Edelman
{"title":"The PACIFIC Trial—Where Do We Go from Here in Immunotherapy for Non-small Cell Lung Cancer?","authors":"M. Edelman","doi":"10.17925/OHR.2018.14.2.65","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.2.65","url":null,"abstract":"","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597504","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.2.74
U. Vaishampayan
Support: No funding was received in the publication of this article. In recent years, personalized therapies have transformed the management of many advanced malignancies. However, despite advances in targeted therapy and immunotherapy that have expanded the treatment options for patients with metastatic kidney cancer, we are unable to predict which patients are most likely to respond to individual treatments. With a number of highly effective therapies available, it is becoming increasingly important to develop a more tailored approach to treatment selection.
{"title":"Personalized Therapy in Advanced Renal Cancer","authors":"U. Vaishampayan","doi":"10.17925/OHR.2018.14.2.74","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.2.74","url":null,"abstract":"Support: No funding was received in the publication of this article. In recent years, personalized therapies have transformed the management of many advanced malignancies. However, despite advances in targeted therapy and immunotherapy that have expanded the treatment options for patients with metastatic kidney cancer, we are unable to predict which patients are most likely to respond to individual treatments. With a number of highly effective therapies available, it is becoming increasingly important to develop a more tailored approach to treatment selection.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597624","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.1.20
U. Vaishampayan
{"title":"Changing Paradigms in the Treatment of Renal Cancer","authors":"U. Vaishampayan","doi":"10.17925/OHR.2018.14.1.20","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.1.20","url":null,"abstract":"","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597283","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.2.63
I. Flinn
{"title":"Recent Advances in the Treatment of Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, and Follicular Lymphoma","authors":"I. Flinn","doi":"10.17925/OHR.2018.14.2.63","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.2.63","url":null,"abstract":"","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597489","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.1.18
S. Ramalingam
Support: No funding was received in the publication of this article. Q. Could you tell us a little about the PACIFIC trial in stage III nonsmall cell lung cancer (NSCLC)? The PACIFIC trial evaluated the role of durvalumab, a programmed death-ligand 1 (PD-L1) antibody, in patients with locally advanced, surgically unresectable stage III NSCLC. Following completion of chemotherapy and radiation, patients were randomized to receive one year of durvalumab or placebo. There was a significant improvement in progression-free survival (PFS) with durvalumab, with a hazard ratio of 0.52. The survival data are awaited. The results of the PACIFIC study have defined a new role for immunotherapy in the treatment of NSCLC. Clinical benefit was seen regardless of PD-L1 expression status.
{"title":"New Advances in the Treatment of Non-Small Cell Lung Cancer","authors":"S. Ramalingam","doi":"10.17925/OHR.2018.14.1.18","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.1.18","url":null,"abstract":"Support: No funding was received in the publication of this article. Q. Could you tell us a little about the PACIFIC trial in stage III nonsmall cell lung cancer (NSCLC)? The PACIFIC trial evaluated the role of durvalumab, a programmed death-ligand 1 (PD-L1) antibody, in patients with locally advanced, surgically unresectable stage III NSCLC. Following completion of chemotherapy and radiation, patients were randomized to receive one year of durvalumab or placebo. There was a significant improvement in progression-free survival (PFS) with durvalumab, with a hazard ratio of 0.52. The survival data are awaited. The results of the PACIFIC study have defined a new role for immunotherapy in the treatment of NSCLC. Clinical benefit was seen regardless of PD-L1 expression status.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.1.38
A. Calvo, Gabriel Ibarra, C. Vibat, Veena Singh
Initial diagnostic biopsy procedures often yield insufficient tissue for molecular testing, and invasive surgical biopsies can be associated with significant cost as well as risk to the patient. Liquid biopsy offers an alternative and economical means for molecular characterization of tumors via a simple peripheral blood draw. This case report describes the ability of liquid biopsy to detect an ALK translocation where tissue analysis by fluorescence in situ hybridization was negative for the genetic alteration. Identification of an ALK rearrangement in circulating tumor cells from a blood specimen led to sequential targeted therapies that included crizotinib followed by alectinib. The patient demonstrated outstanding clinical response during treatment with each of the prescribed ALK inhibitors. This case demonstrates the clinical utility of Biocept’s liquid biopsy to detect actionable biomarkers by surveying the systemic landscape of a patient’s disease where identification of the same genetic drivers may be missed in analyses of heterogeneous tumor tissue.
{"title":"Detecting an ALK Rearrangement via Liquid Biopsy Enabled a Targeted Therapy-based Approach for Treating a Patient with Advanced Non-small Cell Lung Cancer","authors":"A. Calvo, Gabriel Ibarra, C. Vibat, Veena Singh","doi":"10.17925/OHR.2018.14.1.38","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.1.38","url":null,"abstract":"Initial diagnostic biopsy procedures often yield insufficient tissue for molecular testing, and invasive surgical biopsies can be associated with significant cost as well as risk to the patient. Liquid biopsy offers an alternative and economical means for molecular characterization of tumors via a simple peripheral blood draw. This case report describes the ability of liquid biopsy to detect an ALK translocation where tissue analysis by fluorescence in situ hybridization was negative for the genetic alteration. Identification of an ALK rearrangement in circulating tumor cells from a blood specimen led to sequential targeted therapies that included crizotinib followed by alectinib. The patient demonstrated outstanding clinical response during treatment with each of the prescribed ALK inhibitors. This case demonstrates the clinical utility of Biocept’s liquid biopsy to detect actionable biomarkers by surveying the systemic landscape of a patient’s disease where identification of the same genetic drivers may be missed in analyses of heterogeneous tumor tissue.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2018-01-01DOI: 10.17925/OHR.2018.14.1.16
E. Andreopoulou
Support: No funding was received in the publication of this article. Q. Could you tell us a little about the latest research in organoids and biomimetic platforms in precision medicine? Precision medicine aims to utilize information about a patient’s tumor, including gene alterations that may aid in the identification of effective therapies. Recent advances have allowed researchers to combine genomic analysis with ex vivo drug screens. The opportunity to develop preclinical models that retain the tumor’s basic characteristics provides a platform for biomarker discovery and highthroughput drug screening. Patient-derived tumor xenografts have emerged as powerful systems to study many cancer types by growing tumor cells in immunocompromised mice. Advances in this area have focused on trying to improve engraftment rates and introduce the patient’s own immune cells. For more rapid and less costly screens, the patient’s tumor cells are now also cultured in the laboratory in 3D as organoids, allowing us to screen thousands of candidate drugs and drug combinations that have the potential to be used in the clinic. The future of personalized medicine resides in being able to incorporate cells of the microenvironment in state-of-the-art biomimetic platforms. This method of screening will better account for the influence of the cells that are adjacent to the tumor, known to influence the growth of cancers and their response to treatment.
{"title":"Concepts of Precision Medicine in Breast Cancer","authors":"E. Andreopoulou","doi":"10.17925/OHR.2018.14.1.16","DOIUrl":"https://doi.org/10.17925/OHR.2018.14.1.16","url":null,"abstract":"Support: No funding was received in the publication of this article. Q. Could you tell us a little about the latest research in organoids and biomimetic platforms in precision medicine? Precision medicine aims to utilize information about a patient’s tumor, including gene alterations that may aid in the identification of effective therapies. Recent advances have allowed researchers to combine genomic analysis with ex vivo drug screens. The opportunity to develop preclinical models that retain the tumor’s basic characteristics provides a platform for biomarker discovery and highthroughput drug screening. Patient-derived tumor xenografts have emerged as powerful systems to study many cancer types by growing tumor cells in immunocompromised mice. Advances in this area have focused on trying to improve engraftment rates and introduce the patient’s own immune cells. For more rapid and less costly screens, the patient’s tumor cells are now also cultured in the laboratory in 3D as organoids, allowing us to screen thousands of candidate drugs and drug combinations that have the potential to be used in the clinic. The future of personalized medicine resides in being able to incorporate cells of the microenvironment in state-of-the-art biomimetic platforms. This method of screening will better account for the influence of the cells that are adjacent to the tumor, known to influence the growth of cancers and their response to treatment.","PeriodicalId":44122,"journal":{"name":"Oral History Review","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"67597210","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"历史学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：